Based on findings from a multicenter study of over 1,600 patients, researchers at the European Congress of Radiology suggest the inclusion of autonomous artificial intelligence (AI) triage could facilitate up to a 75 percent reduction in prostate MRI reading workload.
The use of an autonomous artificial intelligence (AI) model for clinically significant prostate cancer (csPCa) detection on magnetic resonance imaging (MRI) demonstrated better accuracy than radiologist readers at three different centers, a finding that could significantly alleviate increasing prostate MRI worklist volume, according to research presented recently at the European Congress of Radiology.
For the study, which involved a total of 1,612 patients from three different facilities, researchers utilized AI as a first reader of prostate MRI scans with a subsequent certainty score determining the next step in the detection pathway. The study authors noted that findings on MRI with high certainty for clinically significant prostate cancer (csPCa) did not proceed to the radiologist worklist whereas cases of “uncertain” findings on MRI were triaged for radiologist review.
The researchers employed a non-inferiority specificity margin of -0.05 to calculate accuracy with the AI assistance pathway whereas radiologist accuracy was determined by comparing their PI-RADS 4 and higher assessments with biopsy findings.
At the first center, involving 689 patients, researchers noted 70 percent accuracy with AI assistance vs. 65 percent with radiologist-only reading. In a cohort of 723 patients at the second facility, the study authors noted a 13 percent higher accuracy with AI assistance (75 percent vs. 62 percent), and nearly equivalent accuracy (85 percent vs. 83 percent) at a third center with 200 patients.
“The AI-supported PCa detection pathway provided a more efficient diagnosis compared to the radiologist-only pathway while maintaining a similar accuracy and non-inferior specificity,” wrote lead study author Stefan J. Fransen, MSc, who is affiliated with the Department of Radiology at University Medical Center Groningen in Groningen, Netherlands, and colleagues.
Given workforce shortages in the field and increasing imaging volume, the researchers said the utility of AI could have a significant impact in reserving the more complex diagnostic cases for radiologist review.
“This study shows the feasibility of using uncertainty to triage PCa suspicious patients to AI reading or (radiologist) assessment,” added Fransen and colleagues. “Based on our findings, AI-supported uncertainty-based diagnosis could reduce the radiologist workload by 50% to 75% without losing diagnostic accuracy.”
The researchers cautioned that subsequent prospective studies are necessary to provide more clarity on AI performance and the impact upon radiologist workloads.
Reference
1. Fransen S, Bosma J, van Lohuizen Q, et al. A multi-center validation of prediction uncertainty to select patients for prostate cancer AI diagnosis. Presented at the European Congress of Radiology, February 28-March 3, 2024, Vienna, Austria. https://www.myesr.org/congress/
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.